Moderna(MRNA)

CAMBRIDGE, MABiotechnology1 H-1B visas (FY2023)

Focus: Moderna is a Cambridge-based mRNA therapeutics company with 5,900 employees and a $6.8B revenue run rate (FY2025), focused on vaccines and oncology across infectious disease and rare disease indications. The company is a public, large-cap biotech leader in the mRNA space with proven commercial execution via Spikevax.

Vaccines Oncology Rare Diseases Infectious Disease

Profile data last refreshed 3h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

5,900

Open Jobs

178+26 this month

Hot — 64 jobs added in 30d

Net +26 (64 new, 38 removed). Aggressive expansion phase.

Should You Work at Moderna?

AI assessment

Moderna is a high-growth mRNA platform play with significant near-term pipeline catalysts and hiring momentum, but faces revenue volatility and burn-rate risk that demands strong pipeline execution.

Why Work Here

Pioneer a validated platform technology (mRNA) with commercial proof-of-concept and expanding indications across vaccines, oncology, and rare disease

Data completeness

6/9 — Partial

Company HealthStrong

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$6.8B

Key Products

Spikevax

SARS-CoV-2 infection

Launch

Flagship product with global adoption but facing endemic demand normalization post-pandemic; multiple variant formulations in development (mRNA-1273.214, mRNA-1283, mRNA-1273.211).

Help build intelligence for Moderna

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind

SARS-CoV-2

N/A

Clinical Trials (1)

NCT05367908A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind

N/A

COVID-19 Vaccine

Coronavirus Disease (COVID-19)

N/A

Clinical Trials (1)

NCT04941144Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination

N/A

Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study

SARS-CoV-2

N/A

Clinical Trials (1)

NCT04958304Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study

N/A

Wireless wearable digital devices

Healthy Participants

N/A

Clinical Trials (1)

NCT05440318Use of Wearable Digital Sensors After mRNA Vaccination in Adults

N/A

Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-127

SARS-CoV-2

N/A

Clinical Trials (1)

NCT04958954Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States

N/A

A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults

SARS-CoV-2

N/A

Clinical Trials (1)

NCT05366322A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults

N/A

Moderna COVID-19 Vaccine

COVID-19

N/A

Clinical Trials (1)

NCT05765578An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)

N/A

mRNA-1273

Myocarditis, Pericarditis

N/A

Clinical Trials (1)

NCT06113692A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine

N/A

CMV PCR on saliva

Cytomegalovirus Infections

N/A

Clinical Trials (1)

NCT06522880Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study

N/A

A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccin

Myocarditis

N/A

Clinical Trials (1)

NCT06189053A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)

N/A

Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2

SARS-CoV-2

N/A

Clinical Trials (1)

NCT05894590Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19

N/A

SPIKEVAX Bivalent

SARS-CoV-2

N/A

Clinical Trials (1)

NCT06333704Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE

N/A

mRNA-1345

Respiratory Syncytial Virus

N/A

Clinical Trials (1)

NCT05572658Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

N/A

mRNA-1273

Covid19

N/A

Clinical Trials (1)

NCT05054218COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

N/A

No intervention

SARS-CoV-2 Infection

N/A

Clinical Trials (1)

NCT05794412Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study

N/A

Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrom

SARS-CoV-2

N/A

Clinical Trials (1)

NCT05894499Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19

N/A

"The MaP Study": Mapping the Patient Journey in MMA and PA

Methylmalonic Acidemia

N/A

Clinical Trials (1)

NCT03484767"The MaP Study": Mapping the Patient Journey in MMA and PA

N/A

A Study of the Effectiveness of Moderna COVID-19 Vaccine

SARS-CoV-2

N/A

Clinical Trials (1)

NCT05933304A Study of the Effectiveness of Moderna COVID-19 Vaccine

N/A

Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe

SARS-CoV-2

N/A

Clinical Trials (1)

NCT05894525Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine

N/A

A Retrospective Study to Characterize Participants With Propionic Acidemia

Propionic Acidemia

N/A

Clinical Trials (1)

NCT05769621A Retrospective Study to Characterize Participants With Propionic Acidemia

N/A

Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy

Maternal Outcomes

N/A

Clinical Trials (1)

NCT06369272Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy

N/A

Patient letter and clinician communication

COVID-19 Immunisation

N/A

Clinical Trials (1)

NCT06646406Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate

N/A

SPIKEVAX

SARS-CoV-2

N/A

Clinical Trials (1)

NCT06130345Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

N/A

Patient Reported Outcomes

Multiple Myeloma

N/A

Clinical Trials (1)

NCT05831787COVID19 OutcomeS in Myeloma and the Impact of VaCcines

N/A

mRNA -1215

Nipah Virus Infection

PHASE_1

mRNA-1653

Human Metapneumovirus and Human Parainfluenza Infection

PHASE_1

Clinical Trials (1)

NCT04144348Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Phase 1

mRNA-2752

Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma

PHASE_1

Clinical Trials (1)

NCT03739931Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Phase 1

VAL-339851

Influenza

PHASE_1

Clinical Trials (1)

NCT03345043Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects

Phase 1

mRNA-1645-eODGT8

HIV Infections

PHASE_1

mRNA-1893

Zika Virus

PHASE_1

Clinical Trials (1)

NCT04064905Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

Phase 1

Core-g28v2 60mer mRNA Vaccine

Hiv

PHASE_1

Clinical Trials (1)

NCT05001373A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Phase 1

mRNA-1653

Human Metapneumovirus and Human Parainfluenza Infection

PHASE_1

Clinical Trials (1)

NCT03392389Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

Phase 1

mRNA-1325

Zika Virus

PHASE_1

Clinical Trials (1)

NCT03014089Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects

Phase 1

mRNA-1345

Respiratory Syncytial Virus

PHASE_1

Clinical Trials (1)

NCT04528719A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

Phase 1

V941

Neoplasms

PHASE_1

mRNA-1647

Cytomegalovirus Infection

PHASE_1

Clinical Trials (1)

NCT03382405Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults

Phase 1

mRNA-1273

COVID-19

PHASE_1

mRNA-4157

Solid Tumors

PHASE_1

Pembrolizumab

Carcinoma, Intraductal, Noninfiltrating

PHASE_1

mRNA-1010

SARS-CoV-2

PHASE_1

Clinical Trials (1)

NCT05585632A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

Phase 1

mRNA-4106

Advanced Solid Tumors

PHASE_1

Clinical Trials (1)

NCT06880549A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

Phase 1

mRNA-1283

SARS-CoV-2

PHASE_1

Clinical Trials (1)

NCT04813796A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

Phase 1

mRNA-1647

Cytomegalovirus Infection

PHASE_1

Clinical Trials (1)

NCT05105048A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

Phase 1

mRNA-0184

Healthy Participants

PHASE_1

Clinical Trials (1)

NCT06655870A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants

Phase 1

IMA203

Cutaneous Melanoma

PHASE_1

Clinical Trials (1)

NCT06946225ACTengine® IMA203 Combined With mRNA-4203

Phase 1

VAL-181388

Chikungunya Virus

PHASE_1

Clinical Trials (1)

NCT03325075Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants

Phase 1

mRNA-0184

Chronic Heart Failure

PHASE_1

Clinical Trials (1)

NCT05659264A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

Phase 1

mRNA-1273

COVID-19

PHASE_1

mRNA-1195.1

Epstein-Barr Virus Infection

PHASE_1

Clinical Trials (1)

NCT05831111A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

Phase 1

mRNA-6231

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT04916431A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults

Phase 1

Moderna(MRNA)

Should You Work at Moderna?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (2)

Pipeline & Clinical Trials

Recent News · Moderna(10)

Open Jobs (178)

Lead Resilience R&D Partnerships, Canada

Manager, Real-World Evidence Analytics

Scientist, In Vitro Biology

Executive Director, CMC Regulatory Science

2026 Co-Op, Engineering Instruments & Controls

2026 Co-Op, DNA Specialists

Co-Op, Clinical Biomarker Laboratory, Immuno-Assays

(Fixed Term) Analyst, Quality Control, Chemistry & Stability

Sr. Digital Manufacturing Technical Specialist

Engineer II, Drug Product Development

Sr. Product Manager, Clinical Biomarker Systems

Director, Process Development

2026 Co-Op, Process Automation and Drug Product

Research Associate, Infectious Disease Virology

CMC Digital Support Lead

Country Head, Regulatory Affairs, Australia and New Zealand

Sr. Manager, CMC Stability

Associate Director, Stability Lead Development & Clinical

Director, HR Business Partner, US Commercial

Tax Operations Support

Associate Director, Resilience Strategic Partnerships – UK

Research Associate, Analytical Technical Operations

Principal Research Associate, Analytical Technical Operations

Sr. Research Associate, Analytical Technical Operations

Director, Strategic Forecasting, Oncology

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Research Publications(10)